Serological Test for Influenza Disease Diagnostics Market Research Report – Segmentation By Influenza Type (Type A, Type B, Type C); By End-Use (Hospital, POCT, and Laboratories); and Region - Size, Share, Growth Analysis | Forecast (2024 – 2030)
Published: 2024 - January
Report Code: IM-13056
Format:
Region: Global
Chapter 1.SEROLOGICAL TEST FOR INFLUENZA DISEASE DIAGNOSTICS MARKET – Scope & Methodology
1.1. Market Segmentation
1.2. Assumptions
1.3. Research Methodology
1.4. Primary Sources
1.5. Secondary Sources
Chapter 2.SEROLOGICAL TEST FOR INFLUENZA DISEASE DIAGNOSTICS MARKET – Executive Summary
2.1. Market Size & Forecast – (2023 – 2030) ($M/$Bn)
2.2. Key Trends & Insights
2.3. COVID-19 Impact Analysis
2.3.1. Impact during 2023 - 2030
2.3.2. Impact on Supply – Demand
Chapter 3.SEROLOGICAL TEST FOR INFLUENZA DISEASE DIAGNOSTICS MARKET – Competition Scenario
3.1. Market Share Analysis
3.2. Product Benchmarking
3.3. Competitive Strategy & Development Scenario
3.4. Competitive Pricing Analysis
3.5. Supplier - Distributor Analysis
Chapter 4.SEROLOGICAL TEST FOR INFLUENZA DISEASE DIAGNOSTICS MARKET - Entry Scenario
4.1. Case Studies – Start-up/Thriving Companies
4.2. Regulatory Scenario - By Region
4.3 Customer Analysis
4.4. Porter's Five Force Model
4.4.1. Bargaining Power of Suppliers
4.4.2. Bargaining Powers of Customers
4.4.3. Threat of New Entrants
4.4.4. Rivalry among Existing Players
4.4.5. Threat of Substitutes
Chapter 5. SEROLOGICAL TEST FOR INFLUENZA DISEASE DIAGNOSTICS MARKET - Landscape
5.1. Value Chain Analysis – Key Stakeholders Impact Analysis
5.2. Market Drivers
5.3. Market Restraints/Challenges
5.4. Market Opportunities
Chapter 6.SEROLOGICAL TEST FOR INFLUENZA DISEASE DIAGNOSTICS MARKET – By Influenza Type
6.1. Type A
6.2. Type B
6.3. Type C
Chapter 7.SEROLOGICAL TEST FOR INFLUENZA DISEASE DIAGNOSTICS MARKET – By End-Use
7.1. Hospitals
7.2. POCT
7.3. Laboratories
Chapter 8.SEROLOGICAL TEST FOR INFLUENZA DISEASE DIAGNOSTICS MARKET – By Region
8.1. North America
8.2. Europe
8.3. The Asia Pacific
8.4. Latin America
8.5. The Middle East
8.6. Africa
Chapter 9.SEROLOGICAL TEST FOR INFLUENZA DISEASE DIAGNOSTICS MARKET – Company Profiles – (Overview, Product Portfolio, Financials, Developments)
9.1. Hologic
9.2. bioMérieux SA
9.3. Quidel Corporation
9.4. Becton
9.5. Dickinson and Company
9.6. Meridian Bioscience
9.7. GenMark Diagnostics
9.8. Luminex Corporation,
9.9. Tecan Trading AG
9.10. DiaSorin SA,
9.11. altona Diagnostics GmbH
9.12. SEKISUI Diagnostics
9.13. SA Scientific Ltd
9.14. Coris BioConcept SPRL
9.15. ELITech Group
9.16. Mast Group Ltd
9.17. Genome Diagnostics, Pvt. Ltd
Download Sample
Choose License Type
2500
4250
5250
6900
Frequently Asked Questions
In 2022, the Global Serological Test for Influenza Disease Market was valued at $0.8 Billion and is projected to reach a market size of $1.41 Billion by 2030. Over the forecast period of 2023-2030, market is projected to grow at a CAGR of 7.3%.
The Global Serological Test for Influenza Disease Diagnostics Market drivers are an increase in the number of influenza virus patients and another technological advancement.
The Segments under the Global Serological Test for Influenza Disease Diagnostics Market by Type are Type A, Type B, and Type C.
USA is the most dominating country in the North American region for the Global Serological Test for Influenza Disease Diagnostics Market.
Hologic, Inc., bioMérieux SA, Quidel Corporation, Becton, Dickinson and Company, Meridian Bioscience, GenMark Diagnostics, Inc., Luminex Corporation, Tecan Trading AG, DiaSorin SA, altona Diagnostics GmbH, SEKISUI Diagnostics, SA Scientific Ltd., Coris BioConcept SPRL, ELITech Group, Mast Group Ltd., Genome Diagnostics, Pvt. Ltd.
